This advisory introduces readers to digital therapeutics (DTx) and the benefits of their use in behavioral health. It describes the research, regulatory, and reimbursement implications for DTx as well as selection and implementation considerations.

This advisory defines attention deficit hyperactivity disorder in adults, and explains interactions with substance use disorders.

This advisory reviews diabetes and how it relates to mental illness, stress, and substance use disorders. It highlights ways to integrate diabetes care into behavioral health treatment, such as screening and intake, staff education, integrated care, and counseling support.

This advisory gives an overview of extended-release injectable naltrexone for people with opioid dependence. It discusses how it differs from other medication-assisted treatments, safety concerns, and patients most likely to benefit.

This advisory equips substance use treatment and service providers with information about eating disorders and their relationship to substance use disorders. It provides an overview of screening, referrals, and evidence-based treatments for eating disorders and lists resources for more information.